tbuckley/cabot-search huggingface dataset:
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
Authors: Jiandong Zhou, Sharen Lee, Xiansong Wang, Yi Li, William Ka Kei Wu, Tong Liu, Zhidong Cao, Daniel Dajun Zeng, Keith Sai Kit Leung, Abraham Ka Chung Wai, Ian Chi Kei Wong, Bernard Man Yung Cheung, Qingpeng Zhang, Gary Tse
Journal: npj Digital Medicine (2021)

Recent studies have reported numerous predictors for adverse outcomes in COVID-19 disease. However, there have been few simple clinical risk scores available for prompt risk stratification. The objective is to develop a simple risk score for predicting severe COVID-19 disease using territory-wide data based on simple clinical and laboratory variables. Consecutive patients admitted to Hong Kong's public hospitals between 1 January and 22 August 2020 and diagnosed with COVID-19, as confirmed by RT-PCR, were included. The primary outcome was composite intensive care unit admission, need for intubation or death with follow-up until 8 September 2020. An external independent cohort from Wuhan was used for model validation. COVID-19 testing was performed in 237,493 patients and 4442 patients (median age 44.8 years old, 95% confidence interval (CI): [28.9, 60.8]); 50% males) were tested positive. Of these, 209 patients (4.8%) met the primary outcome. A risk score including the following components was derived from Cox regression: gender, age, diabetes mellitus, hypertension, atrial fibrillation, heart failure, ischemic heart disease, peripheral vascular disease, stroke, dementia, liver diseases, gastrointestinal bleeding, cancer, increases in neutrophil count, potassium, urea, creatinine, aspartate transaminase, alanine transaminase, bilirubin, D-dimer, high sensitive troponin-I, lactate dehydrogenase, activated partial thromboplastin time, prothrombin time, and C-reactive protein, as well as decreases in lymphocyte count, platelet, hematocrit, albumin, sodium, low-density lipoprotein, high-density lipoprotein, cholesterol, glucose, and base excess. The model based on test results taken on the day of admission demonstrated an excellent predictive value. Incorporation of test results on successive time points did not further improve risk prediction. The derived score system was evaluated with out-of-sample five-cross-validation (AUC: 0.86, 95% CI: 0.82-0.91) and external validation (N = 202, AUC: 0.89, 95% CI: 0.85-0.93). A simple clinical score accurately predicted severe COVID-19 disease, even without including symptoms, blood pressure or oxygen status on presentation, or chest radiograph results.
The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation
Authors: Tim D. Holmes, Ram Vinay Pandey, Eric Y. Helm, Heinrich Schlums, Hongya Han, Tessa M. Campbell, Theodore T. Drashansky, Samuel Chiang, Cheng-Ying Wu, Christine Tao, Moneef Shoukier, Eva Tolosa, Sandra Von Hardenberg, Miao Sun, Christian Klemann, Rebecca A. Marsh, Colleen M. Lau, Yin Lin, Joseph C. Sun, Robert Månsson, Frank Cichocki, Dorina Avram, Yenan T. Bryceson
Journal: Science Immunology (2021)

Epigenetic and functional analyses of human NK cells identify a role for Bcl11b in canonical and adaptive NK cell differentiation.
NHS England agrees deal for gene therapy for spinal muscular atrophy
Authors: Elisabeth Mahase
Journal: BMJ (2021)

NHS England has agreed a deal to ensure that Zolgensma (onasemnogene abeparvovec), a one-off gene therapy medicine, will be made available for patients with spinal muscular atrophy.

The drug, labelled the most expensive in the world at £1.79m a dose (€2.09m; $2.48m), will be sold to the NHS at a discounted rate, although the details …
<i>Notes from the Field: </i>Opioid Overdose Deaths Before, During, and After an 11-Week COVID-19 Stay-at-Home Order — Cook County, Illinois, January 1, 2018–October 6, 2020
Authors: Maryann Mason, Sarah B. Welch, Ponni Arunkumar, Lori Ann Post, Joseph M. Feinglass
Journal: MMWR Morbidity and Mortality Weekly Report (2021)
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
Authors: Yi Sun, Jun Jing, Huan Xu, Lingfan Xu, Hailiang Hu, Cai Tang, Shengzhuo Liu, Qiang Wei, Ruiqi Duan, Ju Guo, Lu Yang
Journal: Journal for ImmunoTherapy of Cancer (2021)

Few patients with prostate cancer benefit from current immunotherapies. Therefore, we aimed to explore new strategies to change this paradigm. Human tissues, cell lines and in vivo experiments were used to determine whether and how N-cadherin impacts the production of programmed death ligand-1 (PD-L1) and indole amine 2,3-dioxygenase (IDO-1) and whether N-cadherin can increase the production of effector (e)Treg cells. Then, we used PC3-bearing humanized non-obese diabetic/severe combined immunodeficiency IL2Rγnull (hNSG) mice with an intravenous injection of human CD34+ hematopoietic stem cells into the tail vein to evaluate whether the N-cadherin antagonist N-Ac-CHAVC-NH2 (designated ADH-1) could improve the therapeutic effect of tumor-infiltrating lymphocyte (TIL)-related treatment. N-cadherin dramatically upregulated the expression of PD-L1 and IDO-1 through IFN-γ (interferongamma) signaling and increasing the production of free fatty acids that could promote the generation of eTreg cells. In preclinical experiments, immune reconstitution mediated by TILs slowed tumor growth and extended the survival time; however, this effect disappeared after immune system suppression by PD-L1, IDO-1 and eTreg cells. Furthermore, ADH-1 effectively reduced immunosuppression and enhanced TIL-related therapy. These data show that the N-cadherin antagonist ADH-1 promotes TIL antitumor responses. This important hurdle must be overcome for tumors to respond to immunotherapy.
Use of e-Cigarettes for Smoking Cessation
Authors: Michael J. Lanspa, Denitza P. Blagev, Sean J. Callahan
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic radiofrequency ablation or surveillance in patients with Barrett’s oesophagus with confirmed low-grade dysplasia: a multicentre randomised trial
Authors: Maximilien Barret, Mathieu Pioche, Benoit Terris, Thierry Ponchon, Franck Cholet, Frank Zerbib, Edouard Chabrun, Marc Le Rhun, Emmanuel Coron, Marc Giovannini, Fabrice Caillol, René Laugier, Jeremie Jacques, Romain Legros, Christian Boustiere, Gabriel Rahmi, Elodie Metivier-Cesbron, Geoffroy Vanbiervliet, Paul Bauret, Jean Escourrou, Julien Branche, Lea Jilet, Hendy Abdoul, Nadira Kaddour, Sarah Leblanc, Michael Bensoussan, Frederic Prat, Stanislas Chaussade
Journal: Gut (2021)

Due to an annual progression rate of Barrett's oesophagus (BO) with low-grade dysplasia (LGD) between 9% and 13% per year endoscopic ablation therapy is preferred to surveillance. Since this recommendation is based on only one randomised trial, we aimed at checking these results by another multicentre randomised trial with a similar design.A prospective randomised study was performed in 14 centres comparing radiofrequency ablation (RFA) (maximum of 4 sessions) to annual endoscopic surveillance, including patients with a confirmed diagnosis of BO with LGD. Primary outcome was the prevalence of LGD at 3 years. Secondary outcomes were the prevalence of LGD at 1 year, the complete eradication of intestinal metaplasia (CE-IM) at 3 years, the rate of neoplastic progression at 3 years and the treatment-related morbidity.125 patients were initially included, of whom 82 with confirmed LGD (76 men, mean age 62.3 years) were finally randomised, 40 patients in the RFA and 42 in the surveillance group. At 3 years, CE-IM rates were 35% vs 0% in the RFA and surveillance groups, respectively (p<0.001). At the same time, the prevalence LGD was 34.3% (95% CI 18.6 to 50.0) in the RFA group vs 58.1% (95% CI 40.7 to 75.4) in the surveillance group (OR=0.38 (95% CI 0.14 to 1.02), p=0.05). Neoplastic progression was found in 12.5% (RFA) vs 26.2% (surveillance; p=0.15). The complication rate was maximal after the first RFA treatment (16.9%).RFA modestly reduced the prevalence of LGD as well as progression risk at 3 years. The risk-benefit balance of endoscopic ablation therapy should therefore be carefully weighted against surveillance in patients with BO with confirmed LGD.NCT01360541.
Folate metabolism: a re-emerging therapeutic target in haematological cancers
Authors: Martha M. Zarou, Alexei Vazquez, G. Vignir Helgason
Journal: Leukemia (2021)

Abstract Folate-mediated one carbon (1C) metabolism supports a series of processes that are essential for the cell. Through a number of interlinked reactions happening in the cytosol and mitochondria of the cell, folate metabolism contributes to de novo purine and thymidylate synthesis, to the methionine cycle and redox defence. Targeting the folate metabolism gave rise to modern chemotherapy, through the introduction of antifolates to treat paediatric leukaemia. Since then, antifolates, such as methotrexate and pralatrexate have been used to treat a series of blood cancers in clinic. However, traditional antifolates have many deleterious side effects in normal proliferating tissue, highlighting the urgent need for novel strategies to more selectively target 1C metabolism. Notably, mitochondrial 1C enzymes have been shown to be significantly upregulated in various cancers, making them attractive targets for the development of new chemotherapeutic agents. In this article, we present a detailed overview of folate-mediated 1C metabolism, its importance on cellular level and discuss how targeting folate metabolism has been exploited in blood cancers. Additionally, we explore possible therapeutic strategies that could overcome the limitations of traditional antifolates.
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
Authors: Jim Baggen, Leentje Persoons, Els Vanstreels, Sander Jansen, Dominique Van Looveren, Bram Boeckx, Vincent Geudens, Julie De Man, Dirk Jochmans, Joost Wauters, Els Wauters, Bart M. Vanaudenaerde, Diether Lambrechts, Johan Neyts, Kai Dallmeier, Hendrik Jan Thibaut, Maarten Jacquemyn, Piet Maes, Dirk Daelemans
Journal: Nature Genetics (2021)
Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients
Authors: Hala T. Borno, Ghilamichael Andemeskel, Nynikka R. Palmer
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma
Authors: Can F. Koyuncu, Cheng Lu, Kaustav Bera, Zelin Zhang, Jun Xu, Paula Toro, German Corredor, Deborah Chute, Pingfu Fu, Wade L. Thorstad, F. Faraji, Justin A. Bishop, Mitra Mehrad, Patricia D. Castro, Andrew G. Sikora, Lester D.R. Thompson, R.D. Chernock, Krystle A. Lang Kuhs, Jingqin Luo, Vlad Sandulache, David J. Adelstein, Shlomo Koyfman, James S. Lewis, Anant Madabhushi
Journal: Journal of Clinical Investigation (2021)

BACKGROUND. Patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) are potentially cured with definitive treatment. However, there are currently no reliable biomarkers of treatment failure for p16+ OPSCC. Pathologist-based visual assessment of tumor cell multinucleation (MN) has been shown to be independently prognostic of disease-free survival (DFS) in p16+ OPSCC. However, its quantification is time intensive, subjective, and at risk of interobserver variability.
Portraits of the people who made vaccines possible
Authors: Alison Shepherd
Journal: BMJ (2021)

A year ago when the pandemic took hold of the world Fran Monks, a British portrait photographer, began to use Zoom to take pictures of people in lockdown all over the world.

Then in December she began a series of portraits of people who had participated in vaccine trials.

“They are ordinary people, driven by a desire to do their bit to help save lives and bring an end to repeated …
Brahma‐Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion
Authors: Yongjie Zhou, Yuwei Chen, Xiaoyun Zhang, Qing Xu, Zhenru Wu, Xiaoyue Cao, Mingyang Shao, Yuke Shu, Tao Lv, Changli Lu, Mingjun Xie, Tianfu Wen, Jiayin Yang, Yujun Shi, Hong Bu
Journal: Hepatology (2021)

Intrahepatic cholangiocarcinoma (iCCA) is closely correlated with hepatic progenitor cell (HPC) expansion and liver fibrosis. Brahma-related gene 1 (Brg1), an enzymatic subunit of the switch/sucrose nonfermentable complex that is critical in stem cell maintenance and tumor promotion, is prominently up-regulated in both HPCs and iCCA; however, its role in this correlation remains undefined.A retrospective cohort study indicated that high Brg1 expression suggests poor prognosis in patients with iCCA. In chronically injured livers induced by a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet or bile duct ligation surgery, HPCs were dramatically activated, as indicated by their enhanced expression of Brg1 and a subset of stem cell markers; however, Brg1 ablation in HPCs strongly suppressed HPC expansion and liver fibrosis. Furthermore, in a chemically induced iCCA model, inhibition of Brg1 by a specific inhibitor or inducible gene ablation markedly improved histology and suppressed iCCA growth. Mechanistically, in addition to transcriptionally promoting both Wnt receptor genes and target genes, Brg1 was found to bind to the β-catenin/transcription factor 4 transcription complex, suggesting a possible approach for regulation of Wnt/β-catenin signaling.We have demonstrated the function of Brg1 in promoting HPC expansion, liver cirrhosis, and, ultimately, iCCA development in chronically injured livers, which is largely dependent on Wnt/β-catenin signaling. Our data suggest that therapies targeting Brg1-expressing HPCs are promising for the treatment of liver cirrhosis and iCCA.
Words in "In A Word"
Authors: C. Brooks Henderson
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
Authors: Jing Quan Lim, Dachuan Huang, Tiffany Tang, Daryl Tan, Yurike Laurensia, Rou-Jun Peng, Esther Kam Yin Wong, Daryl Ming Zhe Cheah, Burton Kuan Hui Chia, Jabed Iqbal, Nicholas Francis Grigoropoulos, Maarja-Liisa Nairismägi, Cedric Chuan Young Ng, Vikneswari Rajasegaran, Huangming Hong, Seok Jin Kim, Junhun Cho, Eric Tse, Benjamin Mow, Qi-Chun Cai, Li-Mei Poon, Qing-qing Cai, Jing Tan, Jason Yongsheng Chan, Johnathan Xiande Lim, Yeow Tee Goh, Colin Phipps, Olaf Rötzschke, Chee Leong Cheng, Jeslin Chian Hung Ha, Lay Poh Khoo, Yvonne Su Ming Loh, Rex Au-Yeung, Thomas Sau-Yan Chan, Yok-Lam Kwong, William Hwang, Won Seog Kim, Jin-Xin Bei, Tongyu Lin, Choon Kiat Ong, Soon Thye Lim
Journal: Leukemia (2021)
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data
Authors: Gemma A Figtree, Stephen T Vernon, Nermin Hadziosmanovic, Johan Sundström, Joakim Alfredsson, Clare Arnott, Vincent Delatour, Margrét Leósdóttir, Emil Hagström
Journal: The Lancet (2021)
P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Authors: Peter S. Grimison, Nicola Jane Lawrence, Martin R. Stockler, Andrew James Martin, Sonia Yip, Nicole Wong, Annie Yeung, Michael Friedlander, Danish Mazhar, Farzana Pashankar, David I. Quinn, Rick Walker, Mark Winstanley, Fritha J. Hanning, Andrew James Weickhardt, Amanda Gwendolyn Stevanovic, Ian D. Davis, Guy C. Toner
Journal: Journal of Clinical Oncology (2017)

TPS4592 Background: Bleomycin, etoposide, cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line chemotherapy for metastatic GCTs. Accelerating regimens by giving them 2-weekly rather than 3-weekly has improved cure rates in other cancers. This is the first international randomised clinical trial for intermediate and poor-risk metastatic extra-cranial GCTs involving both adult and paediatric age groups open to both males and females. We aim to determine if accelerated BEP is superior to standard BEP. Methods: DESIGN: Open-label, randomised, stratified multicentre, 2 stage, phase 3 trial. Primary endpoint for stage I (n = 150) is complete response rate (RR), and for entire trial (n = 500) is progression free survival (PFS). SAMPLE SIZE: 150 and 500 patients gives &gt; 80% power to detect a 20% improvement in RRs and 7% absolute improvement in 2yr PFS, respectively. POPULATION: Males and females aged 11-45 yrs with intermediate or poor-risk metastatic GCTs of the testis, ovary, retroperitoneum or mediastinum for 1st line chemotherapy. TREATMENT:Randomisation 1:1 to 4 cycles of “standard BEP” or “accelerated BEP”: cisplatin 20mg/m2 IV days 1-5; etoposide 100mg/m2 IV days 1-5; bleomycin 30000 IU IV weekly; and pegylated G-CSF 6mg SC on Day 6; given every 3 weeks or every 2 weeks respectively. Accelerated BEP arm receives 4 additional weekly doses of bleomycin. ASSESSMENTS: Response assessments at 30-day safety assessment, and 6 months from randomisation or after all post-chemotherapy intervention is completed. Regular follow-up to 5 years, then annually. Archival tumour tissue and baseline blood collected for translational substudies. STATUS: 27 sites open in ANZ, 34 patients recruited by February 2017. International collaborations with UK (led by Cambridge Clinical Trials Unit) and US (led by Childrens Oncology Group) confirmed with sites expected to open by early 2017, and more sites sought for stage 2. Funded by Cancer Council Australia and Cancer Australia. ANZUP supported by Cancer Australia and previously CINSW. ANZCTR: ACTRN12613000496718. Clinical trial information: NCT02582697.
Stepped Collaborative Care Targeting Posttraumatic Stress Disorder Symptoms and Comorbidity for US Trauma Care Systems
Authors: Douglas Zatzick, Gregory Jurkovich, Patrick Heagerty, Joan Russo, Doyanne Darnell, Lea Parker, Michelle K. Roberts, Rddhi Moodliar, Allison Engstrom, Jin Wang, Eileen Bulger, Lauren Whiteside, Deepika Nehra, Lawrence A. Palinkas, Kathleen Moloney, Ronald Maier
Journal: JAMA Surgery (2021)

To date, few multisite investigations have evaluated early interventions for injured patients with posttraumatic stress disorder (PTSD) symptoms.
Abstract PO-040: Retinal disease diagnosis through an adaptive deep learning model
Authors: Haifeng Wang
Journal: Clinical Cancer Research (2021)

Abstract This research presents an adaptive deep learning model for retinal disease classification based on 3D optical coherence tomography (OCT) images. Computer-aided retinal disorder diagnosis is one of the critical research topics that can benefit the patient care process. 3D medical images can provide more comprehensive information about retinal structures. However, due to the higher data dimension and more complicated data pattern compared to 2D images, 3D image analysis is challenging the performance of many machine learning models. This research aims to develop a machine learning model for retinal disease diagnosis on 3D OCT images. A public dataset, which includes age-related macular degeneration (AMD), diabetic macular edema (DME), and the normal cases, is used in this study. The model includes three main procedures: 1) Image preprocessing is conducted for each cross-sectional retinal image. A novel Hough transform-based line detection approach is developed to extract 3D retinal layers. 2) 3D retinal layer samples are constructed, which are used to optimize an adaptive deep learning model to identify the most effective and efficient model structure. A novel objective function is proposed to optimize the convergence trend in this process. The constructed deep learning structure is based on the search result of a neural architecture space. 3) The optimized deep learning model is trained using the extracted 3D samples. The experimental results show that the proposed model can significantly boost the training efficiency and improve the testing accuracy. Citation Format: Haifeng Wang. Retinal disease diagnosis through an adaptive deep learning model [abstract]. In: Proceedings of the AACR Virtual Special Conference on Artificial Intelligence, Diagnosis, and Imaging; 2021 Jan 13-14. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(5_Suppl):Abstract nr PO-040.